GSK’s (GSK) Buy Rating Reiterated at Shore Capital

Shore Capital restated their buy rating on shares of GSK (LON:GSK) in a research report released on Thursday morning, MarketBeat reports.

Other equities research analysts also recently issued research reports about the company. Jefferies Financial Group boosted their target price on GSK from GBX 2,000 to GBX 2,100 and gave the stock a “buy” rating in a research report on Monday, November 3rd. Berenberg Bank lifted their price objective on GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a research report on Monday, November 24th. Finally, JPMorgan Chase & Co. boosted their price objective on GSK from GBX 1,400 to GBX 1,500 and gave the stock an “underweight” rating in a report on Friday, November 7th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, GSK currently has an average rating of “Hold” and a consensus target price of GBX 1,762.

GSK Trading Down 0.3%

LON:GSK opened at GBX 1,886 on Thursday. GSK has a fifty-two week low of GBX 1,242.50 and a fifty-two week high of GBX 1,909.73. The stock’s 50-day moving average is GBX 1,809.73 and its two-hundred day moving average is GBX 1,601.99. The stock has a market cap of £76.08 billion, a PE ratio of 14.18, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73.

GSK (LON:GSK) last issued its quarterly earnings results on Wednesday, October 29th. The company reported GBX 55 earnings per share for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, equities research analysts forecast that GSK will post 175.980975 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Jonathan Symonds bought 1,650 shares of the business’s stock in a transaction on Monday, December 22nd. The shares were purchased at an average price of GBX 1,810 per share, with a total value of £29,865. Also, insider Wendy Becker bought 441 shares of GSK stock in a transaction on Friday, December 19th. The shares were bought at an average price of GBX 1,809 per share, for a total transaction of £7,977.69. Corporate insiders own 0.20% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.